Puma Biotechnology (NASDAQ:PBYI) Cut to Buy at Wall Street Zen

Wall Street Zen lowered shares of Puma Biotechnology (NASDAQ:PBYI) from a strong-buy rating to a buy rating in a research report report published on Saturday.

Separately, Weiss Ratings lowered Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Puma Biotechnology Stock Down 21.0%

Puma Biotechnology stock opened at $4.73 on Friday. Puma Biotechnology has a fifty-two week low of $2.32 and a fifty-two week high of $6.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.62 and a current ratio of 1.73. The firm’s 50-day simple moving average is $5.01 and its 200 day simple moving average is $4.13. The stock has a market cap of $238.25 million, a PE ratio of 4.83 and a beta of 1.35.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.09 by $0.12. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. The firm had revenue of $54.48 million during the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts predict that Puma Biotechnology will post 0.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of PBYI. Nuveen LLC purchased a new stake in shares of Puma Biotechnology during the 1st quarter valued at approximately $234,000. Kapitalo Investimentos Ltda purchased a new position in Puma Biotechnology in the 2nd quarter valued at approximately $241,000. Ethic Inc. bought a new stake in Puma Biotechnology during the 2nd quarter valued at $51,000. Strs Ohio purchased a new stake in shares of Puma Biotechnology during the first quarter worth $420,000. Finally, Acadian Asset Management LLC lifted its position in shares of Puma Biotechnology by 1.8% during the first quarter. Acadian Asset Management LLC now owns 2,008,146 shares of the biopharmaceutical company’s stock worth $5,940,000 after acquiring an additional 36,018 shares in the last quarter. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.